ABSTRACT OBJECTIVES This study sought to report on the safety of catheter ablation for atrial fibrillation (AF) in patients with prior cerebrovascular events (CVEs), at a large-volume tertiary care center over the course of the past 15 years.
C atheter ablation for atrial fibrillation (AF) is widely practiced and has become an effective treatment for recurrent symptomatic arrhythmia (1) . The risk of procedure-related thromboembolism is reported to be between 0% and 7% but is of primary concern because it is potentially devastating (1) . Refinements in periprocedural anticoagulation strategies and close attention to catheter and sheath manipulation in the left atrium (LA) may have reduced this risk.
AF is an independent cause of cardioembolic events (2), a risk that could be potentiated by an ablation procedure (1, (3) (4) (5) , which creates a thrombogenic milieu (1, 6) . In patients with prior
From the Center for Atrial Fibrillation, Cleveland Clinic Foundation, Cleveland, Ohio. Dr. Tarakji has received speaker honorarium cerebrovascular events, the risk of clinical event recurrence, during or following an ablation procedure, remains unclear. Nevertheless, a prior history of stroke or cerebrovascular event in patients with recurrent symptomatic AF is commonly regarded as a risk marker for thromboembolic event recurrence, discouraging catheter ablation as a therapeutic strategy (4) . However, existing data regarding this issue are limited by small population size and variable periprocedural anticoagulation, which per se affect procedural risk (3, 4, 7) . In contrast, significant bodies of data suggest that ischemic stroke risk increases among patients with prior cerebrovascular events undergoing coronary interventions. However, percutaneous coronary interventions involve aggressive anticoagulation and use a transaortic approach without disruption of left atrial endothelium and therefore generate a different balance of thrombotic potential (8, 9) .
We hypothesized that patients with a prior history of cerebrovascular events are not predisposed to significant risk of clinical recurrence when undergoing catheter ablation for AF without interruption of therapeutic anticoagulation (10, 11) , and should not be 
Hussein et al. Hussein et al. Their demographics are summarized in Table 1 . Patients were predominantly male, age <65 years, with a history of hypertension and no heart failure, with a median CHA2DS2-VASC score of 4. PERIPROCEDURAL ANTICOAGULATION. All patients were on oral anticoagulants before the ablation procedure ( Figure 2 ). These anticoagulants were warfarin (n ¼ 192; 77.7%), dabigatran (n ¼ 32; 13.0%), rivaroxaban (n ¼ 15; 6.1%), or apixaban (n ¼ 8; 3.2%). In 1 patient only, warfarin was discontinued and low-molecular-weight heparin was used for bridging periprocedurally. Overall, the mean INR value for patients who were on warfarin was 2.5 AE 0.7. Subcutaneous low-molecular-weight heparin was administered for patients who were on warfarin but had a subtherapeutic INR level on the day of the procedure. Values are %, mean AE SD, or median (interquartile range).
FIGURE 1 Cerebrovascular Events History
In this study of patients with a prior cerebrovascular event (CVE) taken for atrial fibrillation ablation, the history of CVE was remote in most and only a minority demonstrated residual deficits at time of ablation procedure.
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FI GURE 4 Periprocedural Complications
Incidence of complications was very low. Bleeding accounted for all of these and no embolic event occurred.
FIGURE 2 Periprocedural Anticoagulation
Warfarin was the main anticoagulant used in the studied patient group. INR ¼ international normalized ratio.
Hussein et al. odds ratio: 9.5) and interpreted to indicate that risks were increased by a prior history of stroke or cerebrovascular event (4). However, the anticoagulation protocol differed significantly to ours: warfarin was discontinued and patients bridged periprocedurally with low-molecular-weight heparin. This practice largely has been replaced by continuation of therapeutic anticoagulation at the time of the procedure and stroke incidence with AF ablation procedures has decreased from 5 of 1,000 to 1 to 2 of 1,000 (10, 11, 14) .
AF Ablation in Patients With Prior Cerebrovascular Events
This was virtually universal practice in our cohort and may have had important bearing on our results.
Importantly, the incidence of hemorrhagic complications in this cohort was about 4% and none of these complications was associated with permanent disability. This bleeding event rate is comparable with that of the general population of patients undergoing AF ablation at our institution, which had ranged between 1% and 4% (10,11). Hussein et al.
